Skip to main content
Top

Breast Cancer Research and Treatment

Issue 3/2020

Content (26 Articles)

Coronavirus Editorial

Purposeful surgical delay and the coronavirus pandemic: how will black breast cancer patients fare?

Samilia Obeng-Gyasi, Bridget Oppong, Electra D. Paskett, Maryam Lustberg

The influence of mastectomy and reconstruction on residual upper limb function in breast cancer survivors

Meghan E. Vidt, John Potochny, Daleela Dodge, Michael Green, Kathleen Sturgeon, Rena Kass, Kathryn H. Schmitz

Meta-analysis of prepectoral implant-based breast reconstruction: guide to patient selection and current outcomes

Olivia Abbate, Nikki Rosado, Nikhil Sobti, Brittany L. Vieira, Eric C. Liao

Hormone replacement therapy and mammographic density: a systematic literature review

Shadi Azam, Katja Kemp Jacobsen, Arja R. Aro, Elsebeth Lynge, Zorana Jovanovic Andersen

Open Access Breast Cancer Preclinical study

The prognostic significance of BMI1 expression in invasive breast cancer is dependent on its molecular subtypes

Maryam Althobiti, Abir A. Muftah, Mohammed A. Aleskandarany, Chitra Joseph, Michael S. Toss, Andrew Green, Emad Rakha

Breast Cancer Preclinical study

PIBF1 suppresses the ATR/CHK1 signaling pathway and promotes proliferation and motility of triple-negative breast cancer cells

Eun Ji Ro, Seung-Hee Ryu, Eun-Young Park, Je-Won Ryu, Sang Jun Byun, Seung-Ho Heo, Kang Hyun Kim, In-Jeoung Baek, Byung Ho Son, Sang-Wook Lee

Breast Cancer Preclinical study

ETS transcription factor ESE-1/Elf3 is an independent prognostic factor of survival in HR+HER2+ breast cancer patients

Adwitiya Kar, Karen Koto, Darius Walker, Tammy Trudeau, Susan Edgerton, Ann Thor, Arthur Gutierrez-Hartmann

Breast Cancer Clinical trial

N083E (Alliance): long-term outcomes of patients treated in a pilot phase II study of docetaxel, carboplatin, trastuzumab, and lapatinib as adjuvant therapy for early-stage HER2-positive breast cancer

Roberto A. Leon-Ferre, Edith A. Perez, David W. Hillman, Celyne Bueno, Alejandra T. Perez, Beiyun Chen, Robert B. Jenkins, Donald W. Northfelt, David B. Johnson, Robert L. Carolla, Robin T. Zon, Alvaro Moreno-Aspitia

Breast Cancer Clinical Trial

The effect of 1-day multidisciplinary clinic on breast cancer treatment

Zohaib Akhtar, Vered Stearns, Paul Cartwright, Amanda L. Blackford, Vishnu Prasath, Catherine Klein, Danijela Jelovac, Fariba Asrari, Mehran Habibi

Sarcopenia Clinical trial

The association of body composition parameters and adverse events in women receiving chemotherapy for early breast cancer

G. F. P. Aleixo, S. S. Shachar, A. M. Deal, K. A. Nyrop, H. B. Muss, Y. T. Chen, H. Yu, G. R. Williams

Breast Cancer Clinical trial

Plasma DNA as a “liquid biopsy” incompletely complements tumor biopsy for identification of mutations in a case series of four patients with oligometastatic breast cancer

Mary D. Chamberlin, Jason D. Wells, Kevin Shee, Jennifer R. Bean, Jonathan D. Marotti, Wendy A. Wells, Heidi W. Trask, Fred W. Kolling, Ananta Bhatt, Peter A. Kaufman, Gary N. Schwartz, John M. Gemery, Nancy J. McNulty, Michael J. Tsapakos, Richard J. Barth, Bradley A. Arrick, Jiang Gui, Todd W. Miller

Mastectomy Clinical trial

High-Efficiency Same-Day Approach to Breast Reconstruction During the COVID-19 Crisis

Michelle Specht, Nikhil Sobti, Nikki Rosado, Eleanor Tomczyk, Olivia Abbate, Dan Ellis, Eric C. Liao

Open Access Breast Cancer Clinical trial

Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study

Binghe Xu, Wei Li, Qingyuan Zhang, Zhimin Shao, Qiao Li, Xiaojia Wang, Huiping Li, Tao Sun, Yongmei Yin, Hong Zheng, Jifeng Feng, Hong Zhang, Guiyuan Lei, Eleonora Restuccia

Open Access Mastectomy Epidemiology

Impact of chemotherapy, radiotherapy, and endocrine therapy on sick leave in women with early-stage breast cancer during a 5-year period: a population-based cohort study

Anna Plym, Anna L. V. Johansson, Hannah Bower, Anna-Karin Wennstig, Irma Fredriksson, Johan Ahlgren, Mats Lambe

Open Access Mastectomy Epidemiology

Breast-contour preserving procedures for early-stage breast cancer: a population-based study of the trends, variation in practice and predictive characteristics in Denmark and the Netherlands

E. Heeg, M. B. Jensen, M. A. M. Mureau, B. Ejlertsen, R. A. E. M. Tollenaar, P. M. Christiansen, M. T. F. D. Vrancken Peeters

Nausea Epidemiology

Cisplatin given at three divided doses for three consecutive days in metastatic breast cancer: an alternative schedule for one full dose with comparable efficacy but less CINV and hypomagnesaemia

Jinfeng Zhang, Mingxi Lin, Yizi Jin, Linhan Gu, Ting Li, Baoying Yuan, Biyun Wang, Leiping Wang, Sheng Zhang, Jun Cao, Zhonghua Tao, Jian Zhang, Xichun Hu

Breast Cancer Epidemiology

A 15-year follow-up study on long-term adherence to health behaviour recommendations in women diagnosed with breast cancer

Daniel N. Tollosa, Elizabeth Holliday, Alexis Hure, Meredith Tavener, Erica L. James

Breast Cancer Epidemiology

Genetic polymorphisms in DNA repair genes XRCC1 and 3 are associated with increased risk of breast cancer in Bangladeshi population

Nupur Rani Howlader, Md. Mostafizur Rahman, Md. Amir Hossain, Razia Sultana, Syed Mozammel Hossain, Md. Abdul Mazid, Md. Mustafizur Rahman

Breast Cancer Brief Report

Neoadjuvant chemotherapy modifies serum pyrrolidone carboxypeptidase specific activity in women with breast cancer and influences circulating levels of GnRH and gonadotropins

María Jesús Ramírez-Expósito, José Manuel Martínez-Martos, Basilio Dueñas-Rodríguez, Joaquín Navarro-Cecilia, María Pilar Carrera-González

Breast Cancer Correction

Correction to: Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort

Angela S. Cheng, Samuel C. Y. Leung, Dongxia Gao, Samantha Burugu, Meenakshi Anurag, Matthew J. Ellis, Torsten O. Nielsen

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine